ReviewCrohn's & colitis 3602021

The Great Debate With IBD Biosimilars: Pro: Biosimilars Should Be Routinely Used as a First Line Biologic and May Be Switched From Reference Biologics.

Jimmy K Limdi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.